SCHEMBL62892

SCHEMBL62892

CNCCF

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17480237 1.00
Hydrochloric Acid SCHEMBL51439 0.96
Acetic Acid SCHEMBL3002126 0.82
SCHEMBL3315083 0.79
SCHEMBL12582141 0.77
Hydrochloric Acid SCHEMBL16763876 0.74
SCHEMBL7051100 0.74
SCHEMBL13805683 0.72
Hydrochloric Acid SCHEMBL21855052 0.72
SCHEMBL7644680 0.72 EPHX1 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521396-B2 Substituted (thioxo)carbonylaminophenyluracils BAYER CROPSCIENCE AG (DE) 2009-04-21 US claimed
US-20060089262-A1 Substituted (thioxo)carbonylamino phenyl uraciles BAYER CROPSCIENCE AG (DE) 2006-04-27 US claimed
EP-1503994-A1 SUBSTITUTED (THIOXO)CARBONYLAMINO PHENYL URACILES Bayer CropScience AG (DE) 2005-02-09 EP claimed
WO-2003093244-A1 SUBSTITUTED (THIOXO)CARBONYLAMINO PHENYL URACILES BAYER CROPSCIENCE AG (DE) 2003-11-13 WO claimed
US-12637413-B2 Fatty acid amide hydrolase (FAAH) cleavable prodrugs of thyromimetics and combination with peripherally restricted FAAH inhibitors AUTOBAHN THERAPEUTICS, INC. (US) 2026-05-26 US disclosed
US-20260132130-A1 INHIBITORS OF NLRP3 INFLAMMASOME BIOAGE LABS INC (US) 2026-05-14 US disclosed
US-12559462-B2 Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-12509459-B2 Inhibitors of NLRP3 inflammasome BioAge Labs, Inc. 2025-12-30 US disclosed
US-20250304581-A1 INHIBITORS OF NLRP3 INFLAMMASOME BioAge Labs, Inc. 2025-10-02 US disclosed
US-20250270172-A1 Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2025-08-28 US disclosed
EP-4236937-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2025-07-23 EP disclosed
US-20250179057-A1 MEK IMMUNE ONCOLOGY INHIBITORS AND THERAPEUTIC USES THEREOF IMMUNEERING CORPORATION 2025-06-05 US disclosed
WO-1996039407-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1996-12-12 WO disclosed
US-5580872-A ADMINISTERING IN THE TREATMENT OF BACTERIAL INFECTIONS ABBOTT LABORATORIES (US) 1996-12-03 US disclosed
EP-0723545-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1996-07-31 EP disclosed
WO-1995010519-A1 QUINOLIZINONE TYPE COMPOUNDS ABBOTT LABORATORIES (US) 1995-04-20 WO disclosed
US-5407932-A Bactericides WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1995-04-18 US disclosed
EP-0393400-B1 Novel quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same WAKUNAGA SEIYAKU KK (JP) 1994-12-21 EP disclosed
US-5245037-A Synthetic bactericides WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1993-09-14 US disclosed
EP-0393400-A1 Novel quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) 1990-10-24 EP disclosed